Featured Research

from universities, journals, and other organizations

Good provider communication improves antidepressant adherence for diabetes patients

Date:
April 8, 2014
Source:
Kaiser Permanente
Summary:
Adult patients with diabetes who trust their medical provider and feel included in treatment decisions are significantly more likely to take and maintain a newly prescribed antidepressant medication, according to a new study. The study included 1,500 patients with long-standing diabetes, who were prescribed antidepressants.

Adult patients with diabetes who trust their medical provider and feel included in treatment decisions are significantly more likely to take and maintain a newly prescribed antidepressant medication, according to a new study in the Journal of General Internal Medicine.

The study, conducted by researchers at the Kaiser Permanente Division of Research and the University of Washington, School of Medicine, included 1,500 patients with long-standing diabetes, who were prescribed antidepressants.

"In patients with diabetes, depression has been linked to poor self-management and greater risk of diabetic complications including heart disease, dementia, and early mortality," said Andrew Karter, PhD, research scientist at Kaiser Permanente and senior author of the study. "Therefore, care providers believe that adherence to prescribed antidepressants is an important aspect of diabetes care. It is striking how strongly providers' relationships with their patients, particularly establishing trust and the use of shared decision-making, influenced whether patients became ongoing users of the medications prescribed for depression."

Patients with diabetes who were prescribed an antidepressant medication but did not feel included in treatment decisions were more than twice as likely to never fill the prescription. Patients who felt less trust in their provider were also one-third more likely to never refill their prescription after it was first dispensed and to have poor medication adherence during the 12 months after the initial prescription.

For this study, participants rated the quality of communication with their primary care provider during the preceding 12 months. While 96 percent of the patients filled their new antidepressant prescription at least once, rates of never filling were over double (6.1 percent vs. 2.7 percent) among patients who felt less involved in decision-making compared to those who felt more involved. Shared decision-making also was associated with better adherence later in the course of antidepressant treatment, albeit to a lesser degree, suggesting that patients' perceptions of involvement in clinical decisions may have particular significance for adherence in the initial stages of new antidepressant treatment.

"These findings build on previous work in the Diabetes Study of Northern California (DISTANCE) cohort, in which we observed lower adherence to antidepressant medications for patients with limited health literacy," said lead author Amy Bauer, MD, of the University of Washington School of Medicine. "Because the quality of provider communication is potentially modifiable, this serves as a promising target for interventions to improve adherence and therefore help patients get an adequate course of antidepressant therapy. Engaging patients in their care by fostering trust and encouraging shared decision-making is an important part of the therapeutic process that physicians can promote."


Story Source:

The above story is based on materials provided by Kaiser Permanente. Note: Materials may be edited for content and length.


Journal Reference:

  1. Amy M. Bauer, Melissa M. Parker, Dean Schillinger, Wayne Katon, Nancy Adler, Alyce S. Adams, Howard H. Moffet, Andrew J. Karter. Associations Between Antidepressant Adherence and Shared Decision-Making, Patient–Provider Trust, and Communication Among Adults with Diabetes: Diabetes Study of Northern California (DISTANCE). Journal of General Internal Medicine, 2014; DOI: 10.1007/s11606-014-2845-6

Cite This Page:

Kaiser Permanente. "Good provider communication improves antidepressant adherence for diabetes patients." ScienceDaily. ScienceDaily, 8 April 2014. <www.sciencedaily.com/releases/2014/04/140408111719.htm>.
Kaiser Permanente. (2014, April 8). Good provider communication improves antidepressant adherence for diabetes patients. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2014/04/140408111719.htm
Kaiser Permanente. "Good provider communication improves antidepressant adherence for diabetes patients." ScienceDaily. www.sciencedaily.com/releases/2014/04/140408111719.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins